Shanghai Juncell Therapeutics
Shanghai Juncell Therapeutics is a China-based cell therapy company running 2 late-stage cancer trials of GC101 TIL in melanoma and non-small-cell lung cancer.
Overview
Shanghai Juncell Therapeutics, based in Shanghai, China, is a cell therapy company. Juncell Therapeutics is a biotech enterprise focused on research, development and commercialisation of innovative cell therapies for solid tumours, using tumour-infiltrating lymphocyte (TIL) technology platforms. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing GC101 TIL in melanoma and non-small-cell lung cancer. The largest, NCT06703398 (A Study of GC101 TIL in Advanced Melanoma), plans to enrol 98 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Scorecard
All companies- phase 1/2 +1
- targets +6
- modalities +2
Similar pages
not linked directly; found by shared links- CompanyKrystal Biotech
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanymAbxience Research S.L.
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMultitude Therapeutics
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyiOnctura
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyVyriad
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyGeorgiamune
Shares Melanoma and the tag ctgov-sponsor.
- CompanyBioInvent International
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyAvistone Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.